American Journal of Respiratory Cell and Molecular Biology · 2021 · 42 citations · 30 references
Life SciencesInfectious DiseasesMolecular BiologyInnate ImmunityMolecular VirologyVirologyAntiviral ImmunityHost-virus InteractionsViral InfectionsViral PathogenesisAngiotensin-converting Enzyme Inhibitor InteractionsCo-receptor BindingHost Cell Receptor BindingPathogen InfectivitySars-cov-2 InfectionSevere Acute Respiratory SyndromeViral Replication Inhibitors
Abstract Coronavirus disease (COVID-19) is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human SP-D (surfactant protein D) is known to interact with the spike protein of SARS-CoV, but its immune surveillance against SARS-CoV-2 is not known. The current study aimed to examine the potential of a recombinant fragment of human SP-D (rfhSP-D) as an inhibitor of replication and infection of SARS-CoV-2. The interaction of rfhSP-D with the spike protein of SARS-CoV-2 and human ACE-2 (angiotensin-converting enzyme 2) receptor was predicted via docking analysis. The inhibition of interaction between the spike protein and ACE-2 by rfhSP-D was confirmed using direct and indirect ELISA. The effect of rfhSP-D on replication and infectivity of SARS-CoV-2 from clinical samples was assessed by measuring the expression of RdRp gene of the virus using quantitative PCR. In silico interaction studies indicated that three amino acid residues in the receptor-binding domain of spike protein of SARS-CoV-2 were commonly involved in interacting with rfhSP-D and ACE-2. Studies using clinical samples of SARS-CoV-2–positive cases (asymptomatic, n = 7; symptomatic, n = 8) and negative control samples (n = 15) demonstrated that treatment with 1.67 μM rfhSP-D inhibited viral replication by ∼5.5-fold and was more efficient than remdesivir (100 μM) in Vero cells. An approximately two-fold reduction in viral infectivity was also observed after treatment with 1.67 μM rfhSP-D. These results conclusively demonstrate that the rfhSP-D mediated calcium independent interaction between the receptor-binding domain of the S1 subunit of the SARS-CoV-2 spike protein and human ACE-2, its host cell receptor, and significantly reduced SARS-CoV-2 infection and replication in vitro.
30
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu, Dingyu Zhang, Xingwang Li et al. · New England Journal of Medicine · 2020 · 30.4K citations · Full text
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan, Jiwan Ge, Jinfang Yu et al. · Nature · 2020 · 6.7K citations · Full text
Structural basis of receptor recognition by SARS-CoV-2
Jian Shang, Gang Ye, Ke Shi et al. · Nature · 2020 · 4.1K citations · Full text
PatchDock and SymmDock: servers for rigid and symmetric docking
Dina Schneidman‐Duhovny, Yoel Inbar, Ruth Nussinov et al. · Nucleic Acids Research · 2005 · 3.1K citations · Full text